{"pmid":32380474,"title":"Endocrinology in the time of COVID-19: Management of Hyponatraemia and Diabetes Insipidus.","text":["Endocrinology in the time of COVID-19: Management of Hyponatraemia and Diabetes Insipidus.","* COVID-19 has changed the nature of medical consultations, emphasizing virtual patient counseling, with relevance for patients with diabetes insipidus (DI) or hyponatremia. * The principles of management outlined in international guidelines still form the basis of management during COVID-19. * The main complication of desmopressin treatment in DI is dilutional hyponatraemia. Since plasma sodium monitoring is not always possible in times of COVID-19, we recommend to delay the desmopressin dose once a week until aquaresis occurs allowing excess retained water to be excreted. Patients should measure their body weight daily. * Patients with DI admitted to the hospital with COVID-19 have a high risk for mortality due to volume depletion. Endocrinologists must supervise the fluid replacement and dosing of desmopressin. * Patients after pituitary surgery should only drink to thirst and measure their body weight daily to early recognize the development of postoperative SIAD. They should know hyponatraemia symptoms. * Hyponatraemia is common in patients with pneumonia, but it is unclear if it is only a marker of disease severity or if its correction improves outcomes. Its prevalence in patients with pneumonia due to COVID-19 is not yet known, but seems to be low. * In contrast, hypernatraemia may develop in COVID-19 patients in ICU most probably due to insensible water losses from pyrexia, increased respiration rate and use of diuretics. Hypernatraemic dehydration may contribute to the high rate of acute kidney injury in COVID-19. * IV fluid replacement should be administered with caution in severe cases of COVID-19 because of the risk of pulmonary oedema.","Eur J Endocrinol","Christ Crain, Mirjam","Hoorn, Ewout J","Sherlock, Mark","Thompson, Chris J","Wass, John A H","32380474"],"abstract":["* COVID-19 has changed the nature of medical consultations, emphasizing virtual patient counseling, with relevance for patients with diabetes insipidus (DI) or hyponatremia. * The principles of management outlined in international guidelines still form the basis of management during COVID-19. * The main complication of desmopressin treatment in DI is dilutional hyponatraemia. Since plasma sodium monitoring is not always possible in times of COVID-19, we recommend to delay the desmopressin dose once a week until aquaresis occurs allowing excess retained water to be excreted. Patients should measure their body weight daily. * Patients with DI admitted to the hospital with COVID-19 have a high risk for mortality due to volume depletion. Endocrinologists must supervise the fluid replacement and dosing of desmopressin. * Patients after pituitary surgery should only drink to thirst and measure their body weight daily to early recognize the development of postoperative SIAD. They should know hyponatraemia symptoms. * Hyponatraemia is common in patients with pneumonia, but it is unclear if it is only a marker of disease severity or if its correction improves outcomes. Its prevalence in patients with pneumonia due to COVID-19 is not yet known, but seems to be low. * In contrast, hypernatraemia may develop in COVID-19 patients in ICU most probably due to insensible water losses from pyrexia, increased respiration rate and use of diuretics. Hypernatraemic dehydration may contribute to the high rate of acute kidney injury in COVID-19. * IV fluid replacement should be administered with caution in severe cases of COVID-19 because of the risk of pulmonary oedema."],"journal":"Eur J Endocrinol","authors":["Christ Crain, Mirjam","Hoorn, Ewout J","Sherlock, Mark","Thompson, Chris J","Wass, John A H"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32380474","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1530/EJE-20-0338","e_drugs":["Water","Sodium"],"topics":["Prevention"],"weight":1,"_version_":1666262687529566208,"score":9.490897,"similar":[{"pmid":32433817,"title":"Prolonged Confusional state as first manifestation of COVID-19.","text":["Prolonged Confusional state as first manifestation of COVID-19.","A 77 year old gentleman, normally fit and well, was admitted with acute confusion. On admission GCS was 14/15, vital signs were within the normal limits and bilateral crepitation at the lung base. Head CT scan normal. CXR showed some air space opacification. Investigations revealed hyponatraemia, raised CRP and positive for COVID-19. Treated with antibiotics and intravenous saline, sodium returned to normal. Delirium remained unchanged four weeks post incidence. Neurological manifestations were documented in patients with COVID-19, however no report has shown delirium as a primary manifestation. This case illustrates acute confusion may be the only presenting symptom of COVID-19 without overt lung disease.","Ann Clin Transl Neurol","Butt, Isabel","Sawlani, Vijay","Geberhiwot, Tarekegn","32433817"],"abstract":["A 77 year old gentleman, normally fit and well, was admitted with acute confusion. On admission GCS was 14/15, vital signs were within the normal limits and bilateral crepitation at the lung base. Head CT scan normal. CXR showed some air space opacification. Investigations revealed hyponatraemia, raised CRP and positive for COVID-19. Treated with antibiotics and intravenous saline, sodium returned to normal. Delirium remained unchanged four weeks post incidence. Neurological manifestations were documented in patients with COVID-19, however no report has shown delirium as a primary manifestation. This case illustrates acute confusion may be the only presenting symptom of COVID-19 without overt lung disease."],"journal":"Ann Clin Transl Neurol","authors":["Butt, Isabel","Sawlani, Vijay","Geberhiwot, Tarekegn"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32433817","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1002/acn3.51067","keywords":["covid-19","delirium","neuropathology","sars-cov-2"],"topics":["Case Report"],"weight":1,"_version_":1667342288338026497,"score":210.50833},{"pmid":32369770,"title":"Endocrinology in the time of COVID-19: Management of pituitary tumours.","text":["Endocrinology in the time of COVID-19: Management of pituitary tumours.","Patients with pituitary tumours, ensuing hormonal abnormalities and mass effects are usually followed in multidisciplinary pituitary clinics and can represent a management challenge even during times of non-pandemic. The COVID-19 pandemic has put on hold routine medical care for hundreds of millions of patients around the globe, while many pituitary patients' evaluations cannot be delayed for too long. Furthermore, the majority of patients with pituitary tumours have co-morbidities potentially impacting the course and management of COVID-19 (e.g. hypopituitarism, diabetes mellitus, hypertension, obesity, cardiovascular disease). Here, we summarize some of the diagnostic and management dilemmas for these patients, and we provide guidance on safe and as effective as possible delivery of care in the COVID-19 era. We also attempt to address how pituitary services should be remodelled in the event of similar crises, while maintaining or even improving patient outcomes. Regular review of these recommendations and further adjustments are needed, depending on the evolution of the COVID-19 pandemic status. We consider that utilization of successful models of pituitary multidisciplinary care implemented during the COVID-19 pandemic should continue after the crisis is over by using the valuable and exceptional experience gained during these challenging times.","Eur J Endocrinol","Fleseriu, Maria","Karavitaki, Niki","Dekkers, Olaf M","32369770"],"abstract":["Patients with pituitary tumours, ensuing hormonal abnormalities and mass effects are usually followed in multidisciplinary pituitary clinics and can represent a management challenge even during times of non-pandemic. The COVID-19 pandemic has put on hold routine medical care for hundreds of millions of patients around the globe, while many pituitary patients' evaluations cannot be delayed for too long. Furthermore, the majority of patients with pituitary tumours have co-morbidities potentially impacting the course and management of COVID-19 (e.g. hypopituitarism, diabetes mellitus, hypertension, obesity, cardiovascular disease). Here, we summarize some of the diagnostic and management dilemmas for these patients, and we provide guidance on safe and as effective as possible delivery of care in the COVID-19 era. We also attempt to address how pituitary services should be remodelled in the event of similar crises, while maintaining or even improving patient outcomes. Regular review of these recommendations and further adjustments are needed, depending on the evolution of the COVID-19 pandemic status. We consider that utilization of successful models of pituitary multidisciplinary care implemented during the COVID-19 pandemic should continue after the crisis is over by using the valuable and exceptional experience gained during these challenging times."],"journal":"Eur J Endocrinol","authors":["Fleseriu, Maria","Karavitaki, Niki","Dekkers, Olaf M"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32369770","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1530/EJE-20-0473","topics":["Prevention"],"weight":1,"_version_":1666138496277938176,"score":180.14328},{"pmid":32380475,"title":"Endocrinology in the time of COVID-19: Management of Cushing's syndrome.","text":["Endocrinology in the time of COVID-19: Management of Cushing's syndrome.","* Clinical evaluation should guide those needing investigation * Strict adherence to COVID-19 protection measures is necessary * Alternative ways of consultations (telephone, video) should be used * Early discussion with regional/national experts about investigation and management of potential and existing patients is strongly encouraged * Patients with moderate and severe clinical features need urgent investigation and management * Patients with active Cushing's syndrome, especially when severe, are immunocompromised and social shielding is recommended * In patients with mild features or in whom a diagnosis is less likely, clinical re-evaluation should be repeated at three and six months or deferred until the prevalence of SARS-CoV-2 has significantly decreased * Diagnostic pathways may need to be very different from usual recommendations in order to reduce investigations * When extensive differential diagnostic testing is not feasible, it should be deferred, and medical treatment should be initiated * Transsphenoidal pituitary surgery may be avoided during high SARS-CoV-2 viral prevalence * Medical management rather than surgery will be the used for most patients since the short- to mid-term prognosis depends in most cases on hypercortisolism rather than its cause; it should be initiated promptly to minimize the risk of infection in these immunosuppressed patients.","Eur J Endocrinol","Newell-Price, John","Nieman, Lynnette","Reincke, Martin","Tabarin, A","32380475"],"abstract":["* Clinical evaluation should guide those needing investigation * Strict adherence to COVID-19 protection measures is necessary * Alternative ways of consultations (telephone, video) should be used * Early discussion with regional/national experts about investigation and management of potential and existing patients is strongly encouraged * Patients with moderate and severe clinical features need urgent investigation and management * Patients with active Cushing's syndrome, especially when severe, are immunocompromised and social shielding is recommended * In patients with mild features or in whom a diagnosis is less likely, clinical re-evaluation should be repeated at three and six months or deferred until the prevalence of SARS-CoV-2 has significantly decreased * Diagnostic pathways may need to be very different from usual recommendations in order to reduce investigations * When extensive differential diagnostic testing is not feasible, it should be deferred, and medical treatment should be initiated * Transsphenoidal pituitary surgery may be avoided during high SARS-CoV-2 viral prevalence * Medical management rather than surgery will be the used for most patients since the short- to mid-term prognosis depends in most cases on hypercortisolism rather than its cause; it should be initiated promptly to minimize the risk of infection in these immunosuppressed patients."],"journal":"Eur J Endocrinol","authors":["Newell-Price, John","Nieman, Lynnette","Reincke, Martin","Tabarin, A"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32380475","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1530/EJE-20-0352","topics":["Prevention"],"weight":1,"_version_":1666596532356382720,"score":159.12746},{"pmid":32383989,"title":"The Silver Lining to COVID-19: Avoiding Diabetic Ketoacidosis Admissions with Telehealth.","text":["The Silver Lining to COVID-19: Avoiding Diabetic Ketoacidosis Admissions with Telehealth.","Background: The Stay at Home order in Colorado and The Stay Safe at Home order in California during COVID-19 pandemic have forced a majority of the endocrinologists/diabetologists to adapt to providing diabetes care remotely through telehealth. This may provide increased access to diabetes health care in certain settings. However, health care disparities continue to challenge availability of diabetes technologies for underprivileged communities. We report our experience with two patients providing diabetes care effectively and preventing hospital admissions by using telehealth. Methods: Two adult patients with type 1 diabetes (T1D): one new onset and the other one with established T1D are presented where telehealth facilitated by Clarity Software and the \"Share\" feature with the use of Dexcom G6 continuous glucose monitoring (CGM) for management of diabetic ketosis and hyperglycemia. Results: Both patients were managed effectively virtually despite higher risk of diabetic ketoacidosis (DKA). Shared glucose data through CGM facilitated frequent insulin dose adjustments, increased fluid and carbohydrate intake, and prevented hospital admissions in both cases. In the case of new onset patient with T1D, most of the education was done remotely by certified diabetes care and education specialists. Conclusion: Acute diabetes complication like DKA increases morbidity and mortality in addition to adding cost to the health care system. The current pandemic of COVID-19 has allowed newer ways (with the help of newer technologies) to manage high-risk patients with T1D and DKA through telehealth and may result in lasting benefits to people with T1D.","Diabetes Technol Ther","Peters, Anne L","Garg, Satish","32383989"],"abstract":["Background: The Stay at Home order in Colorado and The Stay Safe at Home order in California during COVID-19 pandemic have forced a majority of the endocrinologists/diabetologists to adapt to providing diabetes care remotely through telehealth. This may provide increased access to diabetes health care in certain settings. However, health care disparities continue to challenge availability of diabetes technologies for underprivileged communities. We report our experience with two patients providing diabetes care effectively and preventing hospital admissions by using telehealth. Methods: Two adult patients with type 1 diabetes (T1D): one new onset and the other one with established T1D are presented where telehealth facilitated by Clarity Software and the \"Share\" feature with the use of Dexcom G6 continuous glucose monitoring (CGM) for management of diabetic ketosis and hyperglycemia. Results: Both patients were managed effectively virtually despite higher risk of diabetic ketoacidosis (DKA). Shared glucose data through CGM facilitated frequent insulin dose adjustments, increased fluid and carbohydrate intake, and prevented hospital admissions in both cases. In the case of new onset patient with T1D, most of the education was done remotely by certified diabetes care and education specialists. Conclusion: Acute diabetes complication like DKA increases morbidity and mortality in addition to adding cost to the health care system. The current pandemic of COVID-19 has allowed newer ways (with the help of newer technologies) to manage high-risk patients with T1D and DKA through telehealth and may result in lasting benefits to people with T1D."],"journal":"Diabetes Technol Ther","authors":["Peters, Anne L","Garg, Satish"],"date":"2020-05-09T11:00:00Z","year":2020,"_id":"32383989","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1089/dia.2020.0187","keywords":["cgm","covid-19","diabetic ketoacidosis","health care disparities","new onset type 1 diabetes","telehealth"],"locations":["Colorado","California"],"countries":["United States"],"countries_codes":["USA|United States"],"e_drugs":["Silver","Carbohydrates","Glucose"],"topics":["Prevention"],"weight":1,"_version_":1666419683378593792,"score":156.68036},{"pmid":32396134,"title":"Endocrinology in the time of COVID-19: Management of calcium disorders and osteoporosis.","text":["Endocrinology in the time of COVID-19: Management of calcium disorders and osteoporosis.","Endocrinologists have had to make rapid changes to services so that resources can be focused on the COVID-19 response to help prevent spread of the virus. Herein we provide pragmatic advice on the management of commonly encountered calcium problems and osteoporosis. Non-urgent elective appointments should be postponed, and remote consultations and digital health solutions promoted. Patients should be empowered to self-manage their conditions safely. Patients, their caregivers and healthcare providers should be directed to online resources e.g. Society for Endocrinology, Royal Osteoporosis Society, International Osteoporosis Foundation, specific patient groups and the European Reference Networks (ERNs) for Rare Endocrine and Rare Bone disorders. For patients in acute hospital settings, existing emergency guidance on the management of hyper- and hypo-calcaemia should be followed. A pragmatic, symptom-based approach should be implemented in patients at the end of life. An approach to osteoporosis management is outlined. IV zoledronic acid infusions can be delayed for 6-9 months during the pandemic. Patients established on denosumab and teriparatide should continue planned therapy. The challenge of this pandemic will act as a catalyst to innovate within our management of metabolic bone and mineral disorders to ensure best use of resources and resilience of healthcare systems in its aftermath.","Eur J Endocrinol","Gittoes, Neil J","Criseno, Sherwin","Appelman-Dijkstra, Natasha M","Bollerslev, Jens","Canalis, Ernesto","Rejnmark, Lars","Hassan-Smith, Zaki","32396134"],"abstract":["Endocrinologists have had to make rapid changes to services so that resources can be focused on the COVID-19 response to help prevent spread of the virus. Herein we provide pragmatic advice on the management of commonly encountered calcium problems and osteoporosis. Non-urgent elective appointments should be postponed, and remote consultations and digital health solutions promoted. Patients should be empowered to self-manage their conditions safely. Patients, their caregivers and healthcare providers should be directed to online resources e.g. Society for Endocrinology, Royal Osteoporosis Society, International Osteoporosis Foundation, specific patient groups and the European Reference Networks (ERNs) for Rare Endocrine and Rare Bone disorders. For patients in acute hospital settings, existing emergency guidance on the management of hyper- and hypo-calcaemia should be followed. A pragmatic, symptom-based approach should be implemented in patients at the end of life. An approach to osteoporosis management is outlined. IV zoledronic acid infusions can be delayed for 6-9 months during the pandemic. Patients established on denosumab and teriparatide should continue planned therapy. The challenge of this pandemic will act as a catalyst to innovate within our management of metabolic bone and mineral disorders to ensure best use of resources and resilience of healthcare systems in its aftermath."],"journal":"Eur J Endocrinol","authors":["Gittoes, Neil J","Criseno, Sherwin","Appelman-Dijkstra, Natasha M","Bollerslev, Jens","Canalis, Ernesto","Rejnmark, Lars","Hassan-Smith, Zaki"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32396134","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1530/EJE-20-0385","topics":["Prevention"],"weight":1,"_version_":1666627828056064000,"score":156.08662}]}